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Abstract
Objectives: Familial amyloid polyneuropathy (FAP ATTRV30M) shows a wide
variation in age-at-onset (AO) between clusters, families, and among generations.
We will now explore some candidate genes involved in altered disease pathways
in order to assess their role as genetic modifiers of AO, using a family-centered
approach. Methods: We analyzed 62 tagging SNPs from nine genes-NGAL,
MMP-9, BGN, MEK1, MEK2, ERK1, ERK2, HSP27, and YWHAZ – in a sample of
318 V30M Portuguese patients (106 families), currently under follow-up. A gener-
alized estimating equation analysis was used to take into account nonindepen-
dency of AO between relatives. Also, an in silico analysis was performed in order
to assess the functional impact of significant variants associated with AO. Results:
We found for the first time variants from six genes (NGAL, BGN (in the female
group), MEK1, MEK2, HSP27, and YWHAZ) that were significantly associated
with early- and/or late-onset. Then, we confirmed a strong synergistic interaction
between NGAL and MMP-9 genes. Additionally, by an in silico analysis, we found
some variants for MEK1 gene that may alter binding of the transcription factors
and that influence the regulation of gene expression regarding microRNA binding
sites and splicing regulatory factors. Interpretation: These findings showed that
different genetic factors can modulate differently the onset of disease’s symptoms
and revealed new mechanisms with clinical implications in the genetic counseling
and follow-up of mutation carriers and could contribute for development of
potential therapeutical targets.
Introduction
Familial amyloid polyneuropathy (FAP) ATTRV30M is an
autosomal dominantly (AD) systemic amyloidosis with
variable clinical presentation, age-at-onset (AO), and phe-
notype severity.1 It is characterized by extracellular amy-
loid deposits of fibrillary transthyretin (TTR) that results
in degeneration of the peripheral nerves and it is caused
by a point mutation in the TTR gene (chr18q12.1)
(OMIM 176300). More than 100 different mutations have
been identified,2 but the Val30Met (V30M) missense
mutation is the commonest worldwide.
Typically, a disease of adult-onset,3 FAP ATTRV30M
has not only shown a wide variation in AO between
clusters but also within the same focus.4–8 In Portugal,
where it was first described,3 it was characterized as hav-
ing onset between 25 and 35 years. Nowadays, AO in
Portuguese patients varies from 19–82 years.9 However,
given the large anticipation detected in Portuguese
patients,9 AO variability observed between generations is
our target.
Earlier genetic studies focused on some candidate genes
that can modify AO of FAP ATTRV30M, using a case–
control approach,10,11 but they did not take into account
that early- and late-onset are not separate entities, since
they may coexist within the same family.
In our recent study, we used for the first time a family-
centered approach concluding that amyloid P component,
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serum (APCS) and plasma retinol-binding protein 4
(RBP4) genes have an important role in AO variation and
revealed for the first time the androgen receptor (AR)
gene as an AO modifier both in males and females.12
Now, additional candidate genes related with other FAP
ATTRV30M signaling pathways were selected. We used the
same sample derived from the large Portuguese registry.12
A study using nerve and salivary glands biopsies found
that biglycan (BGN), neutrophil gelatinase-associated
lipocalin (NGAL), and matrix metalloproteinase-9
(MMP-9) proteins were upregulated in FAP ATTRV30M
when compared to controls. BGN seems to be increased
in the earliest stages of TTR deposition in the form of
nonfibrillar aggregates, whereas NGAL and MMP-9 were
only overexpressed at a later stage of disease progression
when fibrillary deposits were formed.13
Monteiro et al., 2006 previously showed that extracellu-
lar signal-regulated kinases 1/2 (ERK1/2) showed
increased activation in FAP ATTRV30M salivary gland
and nerve biopsies. ERK1/2 kinases (MEK1/2) activation
was also upregulated in peripheral nerves, with phospho-
rylation of ERK1/2. Therefore, this may represent an early
signaling cascade leading to cytotoxic effects of TTR
aggregates.14
Furthermore, heat shock proteins (HSPs) have been
involved in several neurodegenerative diseases including
FAP ATTRV30M and an increased expression of heat
shock 27 kDa protein 1 (HSP27) related to the presence
of extracellular TTR deposition in human FAP nerve,
skin, and salivary gland biopsies was found, as compared
to controls.15
Moreover, it has been described that tyrosine 3-mono-
oxygenase/tryptophan 5-monooxygenase activation pro-
tein, zeta (14-3-3zeta or YWHAZ) expression levels
decreased with aging.16 Also, Vieira et al., 2013 showed
that TTR regulates YWHAZ protein levels and so the
absence of TTR correlated with decreased levels of
YWHAZ in the hippocampus in young/adult TTR null
mice when compared to TTR wild-type animals, although
no changes in gene expression were found.17
The aim of our study was to assess for the first time
whether variants in these candidate genes have a modifier
role in AO variation between generations in FAP
ATTRV30M families and to look for a possible interac-
tion between them.
Subjects and Methods
Subjects
From the largest FAP ATTRV30M registry worldwide (at
UCA-CHP, Porto), we collected DNA samples and
clinical data concerning 318 patients (106 families).
Details are described at length at Santos et al., 2016.12
The study was approved by the Ethics Committee of
CHP and all patients gave written informed consent.
DNA extraction
Genomic DNA was extracted from peripheral blood
leukocytes, using the standard salting out method18 or
from saliva, using ORAGENE kits according to the manu-
facturer’s instructions (DNA Genotek, Inc.).
Selection of SNPs and genotyping
A total of 62 tagging single-nucleotide polymorphisms
(SNPs) were selected (Table 1) with Haploview v.4.1,19
using an r2 threshold of 0.80 (as measure of linkage dis-
equilibrium) and with a minor allele frequency of
0.10%.
A multiplex polymerase chain reaction (PCR) amplifi-
cation for 56 tagging SNPs was performed and genotyp-
ing was carried out by a SNaPshot reaction. To genotype
rs350911, rs7698, rs983583, and rs1451637, PCR products
were digested using TfiI, HinP1I, PsiI, and BfaI restriction
enzymes, respectively, and loaded in QIAxcel multicapil-
lary electrophoresis system (Qiagen). The rs12906411 and
rs2289858 genotyping was performed by sequencing. Pri-
mers’ design and genotyping techniques are described in
more detail elsewhere.12
Design and statistical analysis
Our family-centered approach meant that several mem-
bers of the same family were included in the analysis;
therefore, each patient was “nested” in his/her family. We
used generalized estimating equations (GEE),20 since AO
is nonindependent between members of the same family.
The design and statistical analysis were described else-
where.12
Results
We present a family-centered study of variants in nine
candidate genes involved in FAP ATTRV30M signaling
pathway.
In this study with 318 Portuguese FAP ATTRV30M
patients (106 families) with a mean AO of  39 years, we
unraveled for the first time some polymorphisms associ-
ated with AO variation in FAP ATTRV30M, as presented
in Table 2. No significant results were found to be associ-
ated with AO variation regarding MMP-9, ERK1, and
ERK2 genes (data not shown).
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The role of NGAL and BGN genes
In NGAL gene, the CT genotype (P = 0.019) of rs3780836
was significantly associated with an earlier onset corre-
sponding to a decrease of 6 years in mean AO (Table 2).
For the other SNP assessed and for the haplotypic analy-
ses, no significant results were found.
Since BGN gene is located in the X chromosome,
the analyses were stratified by gender and the
genotypic analyses were only performed in the female
group.
Regarding the allelic analyses performed in the male
patients group, no significant result was found associated
with AO (data not shown).
Table 1. Tagging SNPs selected for each gene.
Candidate genes
NGAL MMP-9 BGN MEK1 MEK2 ERK1 ERK2 HSP27 YWHAZ
rs2289860
rs350916
rs1979013
rs1549854 rs350911 rs2276008 rs17365305
rs2266862 rs745796 rs10250 rs13515 rs4734497
rs1805088 rs7062216 rs9672789 rs2289858 rs1063311 rs1376672
rs3918249 rs1126499 rs1432442 rs350903 rs7698 rs2298432 rs17365661
rs12006030 rs3918256 rs2073479 rs12906411 rs10412325 rs1143695 rs7286558 rs11769502 rs7835096
rs3780836 rs3787268 rs2269404 rs16949939 rs350897 rs11865086 rs3827303 rs3134354
rs2250889 rs1042103 rs11630608 rs350895 rs8141815 rs35083016
rs17577 rs743642 rs7181936 rs7258366 rs9610417 rs983583
rs8039880 rs350894 rs5755694 rs1451637
rs1823059
rs12609676
rs12459484
rs350887
Table 2. Significant results of the analysis of NGAL, BGN, MEK1, MEK2, HSP27, and YWHAZ SNPs and AO variation taking into account intrafa-
milial nonindependency.
Gene SNP Genotypes B 95% CI P-value
NGAL rs3780836 CC (reference) – – –
CT 6.07 [11.15; 0.98] 0.019
BGN (female group) rs2269404 CC (reference) – – –
TT 10.48 [1.03; 19.93] 0.030
MEK1 rs8039880 AA (reference) – – –
GG 7.02 [14.03; 0.00] 0.050
rs11630608 TT (reference) – – –
CC 12.75 [20.98; 4.53] 0.002
CT 9.38 [14.21; 4.55] P < 0.001
rs16949939 CC (reference) – – –
CT 26.15 [14.34; 37.96] P < 0.001
rs745796 TT (reference) – – –
CC 10.49 [19.50; 1.47] 0.023
MEK2 rs1823059 CC (reference) – – –
TT 17.08 [4.13; 30.03] 0.010
HSP27 rs11769502 CC (reference) – – –
CT 6.664 [11.30; 2.02] 0.005
YWHAZ rs17365305 GG (reference) – – –
GA 6.759 [12.97; 0.55] 0.033
B, unstandardized coefficient (estimated quantitative effect of each genotype on AO variation compared with the reference genotype); CI, confi-
dence interval; P-value, significance level was set to 0.05.
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Importantly, in the female group, the TT genotype
(P = 0.030) of rs2269404 was significantly associated with
a later AO, an increase of 10 years in disease onset
(Table 2). In the haplotypic analyses performed for the
female group, we found a significant result when the
C-G-T-C-C-A-G haplotype is present (P = 0.036) associ-
ated with a later onset.
Regarding parental transmission for these genes, no sig-
nificant differences were found.
MEK1 and MEK2 genes and AO
For MEK1 gene, we found four SNPs significantly associ-
ated with AO: the CC genotype (P = 0.002) and the CT
genotype (P < 0.001) of rs11630608 and the CC genotype
(P = 0.023) of rs745796 were associated with an earlier
onset and this variation corresponds from 9 to 13 years
in disease onset for these polymorphisms (Table 2). On
the other hand, the CT genotype (P < 0.001) of
rs16949939 was associated with a mean increase of
26 years in AO (Table 2).
Regarding the MEK2 gene, we found that the TT geno-
type (P = 0.010) of rs1823059 was associated with a later
AO, an increase of 17 years (Table 2).
In the haplotypic analyses, no significant results were
found (data not shown).
Concerning parental transmission of the SNPs to the
affected children, we found a differential transmission for
allele C of rs11630608 and allele C of rs745796 in the
MEK1 gene. Nonaffected fathers transmitted more often
than expected these alleles that are involved in an earlier
onset. In addition, for the rs11630608, sons of non-
affected fathers received more often than expected the C
allele (P = 0.012), while for the rs745796, daughters of
non-affected fathers received more often than expected
the C allele (P = 0.013) (data not shown).
Regarding MEK2 gene, for the rs1823059, we found
that nonaffected fathers transmitted more often than
expected the T allele that is associated with a later onset
(P = 0.015). For the other SNPs, we did not find any sig-
nificant differences in parental transmission (data not
shown).
HSP27 and YWHAZ genes and AO variation
We found that the CT genotype (P = 0.005) of
rs11769502 for HSP27 gene and the GA genotype
(P = 0.033) of rs17365305 for YWHAZ gene, were signifi-
cantly associated with earlier onset and the difference cor-
responds to a decrease of 7 years in mean AO (Table 2).
For these genes, we also performed haplotype-based anal-
ysis, but no differences were found (data not shown).
For these genes, no significant differences were found
in parental transmission.
Functional impact and gene–gene
interactions
To explore the functional impact of the SNPs associated
with AO variation, we performed an in silico analysis
using FuncPred and is-rSNP. Particular attention was
paid to rs745796 of MEK1 gene since some SNPs in LD
(rs10851759, rs11071895, rs12914079, rs4776791,
rs7403574, and rs8043062) may alter transcription factors’
binding (TFB) sites. In addition, the is-rSNP algorithm
highlighted that this SNP may also significantly affect the
ability of one transcription factor to bind to DNA
(LM120, P = 0.001) (Fig. 1). This analysis also predicts
that rs537 (which is in LD with rs745796) may affect
microRNA binding sites.
Additionally, we found that rs11071896 and rs17851970
(which are in LD with rs11630608 of MEK1), rs1030986
and rs16953566 (which are in LD with rs16949939 of
MEK1) may alter the recognition sites for splicing regula-
tory factors.
A strong synergistic interaction was found with the
MDR analysis, as shown in the dendogram (Fig. 2) for
the best model, between the rs17577 of the MMP-9 gene
Figure 1. The sequence logo of the one transcription factor (TF) binding site potentially disrupted by MEK1 rs745796.
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and rs12006030 of the NGAL gene, with a testing bal-
anced accuracy (TBA) of 0.59 and a cross-validation con-
sistency (CVC) of 10/10. After permutation testing, this
model was still significant (P = 0.037).
Discussion
Research on age-at-onset (AO) variation has been central
in several dominant diseases including FAP ATTRV30M,
since it might lead to a better understanding of the dis-
ease pathogenesis mechanisms. Thus, this study addresses
the identification of variants of possible candidate genes
as AO genetic modifiers in FAP ATTRV30M. To the best
of our knowledge, this is the first study that examines the
association of these six potential candidate genes (NGAL,
BGN, MEK1, MEK2, HSP27, and YWHAZ) linked to sev-
eral FAP ATTRV30M signaling pathways with AO, using
a family-centered approach.
NGAL and BGN variants associated with AO
variation
We examined variants in genes linked to remodeling of
the extracellular matrix (ECM)-related components as
NGAL, MMP-9, and BGN due to its overexpression in
FAP ATTRV30M. In our sample, we found that the CT
genotype of rs3780836 in the NGAL gene was associated
with an earlier onset and we hypothesize that this variant
could be a genetic risk factor for the FAP ATTRV30M
patients. On the other hand, we found that in the female
group, the rare genotype (TT) of rs2269404 of the BGN
gene was associated with a later onset, leading us to sug-
gest that this variant can have a possible protective effect
in females. We also performed an MDR analysis for
detection of gene–gene interaction, which is a powerful
statistical tool of multilocus data reduction to improve
the detection of genotypic combinations that predict dis-
ease risk.21 We found a strong synergistic interaction
between NGAL and MMP-9 genes, confirmed by a 1000-
fold permutation test. In addition, this study confirm the
data already described in a previous study, using FAP
ATTRV30M nerve and salivary glands biopsies, which
showed that NGAL forms a complex with MMP-9 and
where expression of these genes seems to overlap.13
Therefore, this was the first study that explored the possi-
ble involvement of the variants of these genes associated
with AO variation, using a family-centered approach. Fur-
thermore, NGAL and MMP-9 were only overexpressed at
a later stage when amyloid fibrils were already present,
while BGN was upregulated in the earliest stages of TTR
deposition, when nonfibrillar TTR aggregates were already
present, but could coexist with TTR fibrils.13 Similarly,
Cardoso et al., 2008 corroborated the observations
reported for human tissues,13 but using an FAP
ATTRV30M transgenic mice model.22
Role of MEK1 and MEK2 variants in AO
variability
Although molecular signaling mechanisms in FAP
ATTRV30M are not fully understood, a previous study
provides evidence for the involvement of the MEK-ERK
MAPK signaling pathway in disease pathogenesis.14
Therefore, we selected MEK1/2 and ERK1/2 as candidate
genes due to their role as mediators of the cytotoxic
effects of TTR aggregates in different stages of disease
progression.
In a study using human FAP ATTRV30M nerve biop-
sies, MEK1/2 activation was found upregulated in both
asymptomatic carriers and patients when compared to
controls. Furthermore, phosphorylation levels of MEK1/2
were decreased in later symptomatic stages.14 MEK1/2 is
activated after phosphorylation and may lead to ERK1/2
activation in response to a variety of hormones, growth
factors, and oxidative stress, which can regulate transcrip-
tion and translation.23,24 When ERK signaling cascade is
early activated, it can lead to increased cell proliferation
and TTR aggregates expression levels. This will lead to
cytotoxic effects by TTR aggregates and to an earlier
AO.14 Likewise, it was shown in peripheral nerves of a
FAP transgenic mouse model an increased ERK1/2 activa-
tion when TTR deposits occurs when compared to con-
trol animals, where older animals (17 months) had twice
the activation of younger ones (2 months).14 Additionally,
it was shown a sequential activation of MEK1/2 and
ERK1/2 in brains with early stage of neurofibrillary
degeneration.23
We found that four variants in MEK1 were associated
with an earlier AO and one variant associated with a later
disease onset. Interestingly, we found a differential paren-
tal transmission regarding rs11630608 and rs745796 in
the MEK1 gene where the nonaffected fathers added a
genetic risk effect to AO variation. Moreover, sons of
nonaffected fathers in the case of rs11630608 and daugh-
ters of nonaffected fathers in the case of rs745796 have an
increased susceptibility for earlier AO when they receive
Figure 2. Dendogram showing a strong synergistic interaction
among neutrophil gelatinase-associated lipocalin (NGAL)-MMP-9
genes (darker lines suggest a synergistic relationship – shorter the
lines, stronger the interaction).
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the rare allele (C). Additionally, we found that the
rs1823059 TT genotype of MEK2 was associated with a
later AO. Furthermore, for the rs1823059 in the MEK2
nonaffected fathers added a protector genetic effect to AO
variation leading to a later AO.
The adverse or protective effects associated with early-
and late-onset of MEK1/2 variants point to an effect of
these genes in our sample. We also found a possible mod-
ulatory effect on AO associated with the noncarrier chro-
mosome (a transacting effect).
In silico analysis revealed some variants in LD with
rs745796 of MEK1 gene that may alter binding of the tran-
scription factors LM120 promoting upregulation of this
gene. Furthermore, LM120 was predicted to have more
affinity when the C allele is present, reinforcing our geno-
type analysis where the CC genotype was found to be asso-
ciated with individuals with an earlier AO. As in other
studies, this could lead to an early activation of this path-
way.23 Additionally, we also found other alterations that
could influence the regulation of gene expression regard-
ing microRNA binding sites and splicing regulatory fac-
tors. Therefore, the inhibition or activation of the factors
involved in the MEK1/2 signaling cascade can be good tar-
gets for the development of novel therapeutic approaches.
HSP27 and YWHAZ variants and AO
Several studies have reported the essential role of the heat
shock proteins (HSPs) in various neurodegenerative dis-
orders associated with protein aggregation since these are
considered important for cellular defense mechanisms.
Thus, it was already demonstrated that in the presence of
protein misfolding and aggregation, a neuroprotective
stress response mediated by HSPs can be induced in Alz-
heimer’s disease (AD),25 Parkinson’s disease26, and Hunt-
ington’s disease.27 However, activation of heat shock
transcription factor 1 (HSF) is required for upregulation
of the HSP synthesis. In a previous study, it was shown
that in FAP ATTRV30M human nerve, skin, and salivary
gland biopsies with extracellular TTR deposits, there is
induction of intracellular activation of HSF1 and conse-
quently an increase in the expression of HSP27 and
HSP70.15
In this study, we selected the HSP27 gene in order to
investigate if it influences AO variation, since HSP27
upregulation was only observed in tissues with extracellu-
lar TTR deposition.15 We found that rs11769502 of
HSP27 was associated with an earlier onset, reinforcing
the important role of HSP27 in FAP ATTRV30M. There-
fore, the effect of this variant could induce an early neu-
roprotective intracellular stress response by increasing
HSP27 expression, activating the cell defense mechanism
to prevent neurodegeneration in FAP ATTRV30M.
As with HSPs, YWHAZ protein might act as a neuro-
protection mechanism against toxicity in a variety of neu-
rodegenerative diseases with common cellular and
molecular mechanisms including protein aggregation
since this may function as a sweeper of misfolded pro-
teins.28 In a previous study in AD, the authors found that
YWHAZ stimulates tau phosphorylation29 and is upregu-
lated in the patients’ brains.30 In another study, it was
shown the specificity of TTR to regulate YWHAZ levels
and decreased YWHAZ protein expression in the hip-
pocampus of young/adult TTR null mice when compared
to TTR wild-type animals.17 Also, it was shown that
YWHAZ expression levels decrease with aging.16
We found that rs17365305 of YWHAZ gene was associ-
ated with an earlier onset, leading us to suggest that in
the presence of this variant, the potential risk effect may
be increased and the YWHAZ-related defense mechanisms
blocked. Therefore, the modulation of this variant will be
important in order to protect early-onset patients.
In conclusion, the results of our study provide evidence
for an association of DNA noncoding variants of genes in
FAP ATTRV30M pathways that may have phenotypic
implications, particularly, in AO variation. However, our
study does not preclude the possibility that other genes
involved in these or other pathways may act as genetic
modifiers of AO. Although an in silico analysis has been
performed to predict functional impact of significant vari-
ants, functional studies will be important to deepen our
knowledge. Moreover, in the future, it would also be
interesting to replicate our study in other FAP
ATTRV30M populations.
Therefore, with this study, we reveal for the first time,
using a family-centered approach, that variants of NGAL,
BGN, MEK1, MEK2, HSP27, and YWHAZ may act as
potential genetic modulators of AO in FAP ATTRV30M,
which could be useful for the development of novel thera-
peutic approaches, improve patient care, and aid in the
genetic counseling of mutation carriers.
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